Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Uplizna is part of Amgen’s rare disease franchise and was added to its portfolio following the acquisition of Horizon ...

Amgen has shared new data from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon) in adults with the rare autoimmune disorder generalised myasthenia gravis (gMG). The phase ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of Daily Living score compared to placebo at week 26. Results from the Phase III ...

US biotech major Amgen (Nasdaq: AMGN) has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG). The results ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent player in the biotechnology industry with a market capitalization of $167.88 billion, has announced results from the Phase 3 MINT trial of ...

(RTTNews) - Amgen Inc. (AMGN) Thursday announced positive data from the Phase 3 MINT study of Uplizna in adults with generalized myasthenia gravis (gMG). Myasthenia gravis is a chronic autoimmune ...